Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low - Here's Why

Key Points

• Structure Therapeutics shares fell to a new 52-week low of $20.50, down from the previous close of $21.55. The stock’s market cap is approximately $1.48 billion, with its 50-day and 200-day moving averages at $35.29 and $50.14, respectively.
• The company reported quarterly EPS of -$0.49, missing the consensus estimate of -$0.39; analysts expect a full-year loss of approximately $1.87 per share.
• Analyst sentiment remains mixed but leans positive: the stock has a consensus “Moderate Buy” rating and a $110.91 price target, despite recent downgrades and the sharp decline. Institutional investors own 91.78% of the company.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s stock price reached a new 52-week low on Wednesday. The stock traded as low as $20.50 and last traded at $20.7660, with a volume of 174,301 shares changing hands. The stock had previously closed at $21.55.

Analyst Ratings Changes

A number of equities research analysts have weighed in on GPCR shares. Weiss Ratings downgraded Structure Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. HC Wainwright reiterated a "buy" rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Wall Street Zen lowered Structure Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 3rd. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, Citizens Jmp reiterated a "market outperform" rating and set a $110.00 price target on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.91.

Structure Therapeutics Price Performance

The company has a market cap of $1.48 billion, a P/E ratio of -21.20 and a beta of -1.30. The company's 50-day moving average is $35.29 and its two-hundred day moving average is $50.14.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.87 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sterling Capital Management LLC bought a new position in Structure Therapeutics during the 1st quarter valued at about $28,000. IFP Advisors Inc bought a new stake in shares of Structure Therapeutics during the 2nd quarter worth approximately $46,000. Assetmark Inc. grew its position in Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company's stock valued at $123,000 after acquiring an additional 449 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in Structure Therapeutics in the first quarter worth $329,000. Finally, Cetera Investment Advisers lifted its position in shares of Structure Therapeutics by 17.0% during the first quarter. Cetera Investment Advisers now owns 7,720 shares of the company's stock worth $372,000 after purchasing an additional 1,124 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.